Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products--Quality Considerations
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
April 19, 2018
April 24, 2020
c62dfac7-e8d8-48bb-833a-3c127bd90939
Related Documents
Establishing Impurity Specifications for Antibiotics
Guidance DocumentApril 20, 2026Center for Drug Evaluation and Research
Quality Considerations for Topical Ophthalmic Drug Products
Guidance DocumentDecember 27, 2023Center for Drug Evaluation and Research
Benefit-Risk Considerations for Product Quality Assessments
Guidance DocumentMay 9, 2022Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox